Skip to main content
. 2020 Nov 16;19:240. doi: 10.1186/s12944-020-01418-0

Table 2.

Use of medications, agiographic findings, and procedural results of the study population according to the AIP quartiles

Variable Q1 Q2 Q3 Q4 P value
n = 199 n = 200 n = 200 n = 199 Overall Q2 vs. Q1 * Q3 vs. Q1 * Q3 vs. Q2 * Q4 vs. Q1 * Q4 vs. Q2 * Q4 vs. Q3 *
Medications before admission
 Aspirin, n (%) 145 (72.9) 149 (74.5) 154 (77.0) 146 (73.4) 0.784
 P2Y12 inhibitors, n (%) 81 (40.7) 81 (40.5) 74 (37.0) 80 (40.2) 0.858
 Statins, n (%) 150 (75.4) 143 (71.5) 155 (77.5) 142 (71.4) 0.418
 ACEIs/ARBs, n (%) 55 (27.6) 65 (32.5) 72 (36.0) 69 (34.7) 0.300
 β-blockers, n (%) 70 (35.2) 79 (39.5) 93 (46.5) 63 (31.7) 0.016 0.372 0.021 0.157 0.457 0.102 0.002
 Insulin, n (%) 75 (37.7) 73 (36.5) 79 (39.5) 63 (31.7) 0.406
 Oral antidiabetic agents, n (%) 89 (44.7) 98 (49.0) 110 (55.0) 90 (45.2) 0.145
Intraoperative anticoagulants
 Unfractionated heparin, n (%) 168 (84.4) 170 (85.0) 154 (77.0) 156 (78.4) 0.086
 LMWH, n (%) 6 (3.0) 7 (3.5) 16 (8.0) 10 (5.0) 0.089
 Bivalirudin, n (%) 25 (12.6) 23 (11.5) 30 (15.0) 33 (16.6) 0.448
Perioperative medications
 Aspirin, n (%) 196 (98.5) 198 (99.0) 200 (100.0) 196 (98.5) 0.308
 P2Y12 inhibitors, n (%) 199 (100.0) 200 (100.0) 200 (100.0) 199 (100.0)
 GP IIb/IIIa receptor antagonist, n (%) 29 (14.6) 38 (19.0) 45 (22.5) 37 (18.6) 0.246
Medications at discharge
 Aspirin, n (%) 196 (98.5) 198 (99.0) 200 (100.0) 196 (98.5) 0.308
 Cilostazol, n (%) 3 (1.5) 2 (1.0) 1 (0.5) 4 (2.0) 0.473
 Clopidogrel, n (%) 174 (87.4) 183 (91.5) 178 (89.0) 190 (95.5) 0.031 0.186 0.628 0.399 0.004 0.108 0.016
 Ticagrelor, n (%) 25 (12.6) 17 (8.5) 22 (11.0) 9 (4.5) 0.031 0.186 0.628 0.399 0.004 0.108 0.016
 Statins, n (%) 199 (100.0) 200 (100.0) 200 (100.0) 199 (100.0)
 ACEIs/ARBs, n (%) 81 (40.7) 93 (46.5) 105 (52.5) 121 (60.8) 0.001 0.243 0.018 0.230 < 0.001 0.004 0.094
 β-blockers, n (%) 138 (69.3) 147 (73.5) 155 (77.5) 136 (68.3) 0.155
 Insulin, n (%) 65 (32.7) 76 (38.0) 72 (36.0) 57 (28.6) 0.213
 Oral antidiabetic agents, n (%) 87 (43.7) 120 (60.0) 119 (59.5) 105 (52.8) 0.003 0.001 0.002 0.919 0.071 0.145 0.175
Angiographic findings
 One-vessel disease, n (%) 22 (11.1) 15 (7.5) 18 (9.0) 25 (12.6) 0.347
 Two-vessel disease, n (%) 68 (34.2) 41 (20.5) 42 (21.0) 46 (23.1) 0.004 0.002 0.003 0.902 0.015 0.527 0.610
 LM/three-vessel disease, n (%) 109 (54.8) 144 (72.0) 140 (70.0) 128 (64.3) 0.001 < 0.001 0.002 0.659 0.052 0.100 0.227
 Proximal LAD stenosis, n (%) 94(47.2) 110 (55.0) 97 (48.5) 100 (50.3) 0.428
 Restenotic lesions, n (%) 26 (13.1) 26 (13.0) 30 (15.0) 29 (14.6) 0.913
 Trifurcation or bifurcation lesions, n (%) 155 (77.9) 162 (81.0) 151 (75.5) 148 (74.4) 0.403
 Chronic total occlusions, n (%) 36 (18.1) 46 (23.0) 44 (22.0) 57 (28.6) 0.093
 Thrombus lesions, n (%) 7 (3.5) 14 (7.0) 12 (6.0) 12 (6.0) 0.478
 Heavy calcification lesions, n (%) 75 (37.7) 69 (34.5) 73 (36.5) 48 (24.1) 0.016 0.507 0.806 0.676 0.003 0.023 0.007
 Lesions > 20 mm long, n (%) 108 (54.3) 112 (56.0) 122 (61.0) 117 (58.8) 0.537
Procedural results
 Target vessel territory
 LM, n (%) 13 (6.5) 16 (8.0) 9 (4.5) 18 (9.0) 0.313
 LAD, n (%) 104 (52.3) 97 (48.5) 100 (50.0) 99 (49.7) 0.899
 LCX, n (%) 64 (32.2) 69 (34.5) 42 (21.0) 48 (24.1) 0.007 0.620 0.012 0.003 0.075 0.023 0.456
 RCA, n (%) 69 (34.7) 82 (41.0) 100 (50.0) 74 (37.2) 0.011 0.193 0.002 0.071 0.601 0.435 0.010
 DES use, n (%) 174 (87.4) 172 (86.0) 161 (80.5) 159 (79.9) 0.097
 BRS use, n (%) 6 (3.0) 7 (3.5) 8 (4.0) 11 (5.5) 0.607
 DCB use, n (%) 12 (6.0) 11 (5.5) 19 (9.5) 14 (7.0) 0.409
Complete revascularization, n (%) 136 (68.3) 115 (57.5) 110 (55.0) 107 (53.8) 0.012 0.025 0.006 0.614 0.003 0.453 0.805

* P < 0.0083 is considered statistically significant for post hoc multiple comparisons of categorical variables between groups

AIP Indicates atherogenic index of plasma; ACEIs Angiotensin converting enzyme inhibitors; ARBs Angiotensin II receptor blockers; LM Left-main artery; LAD Left anterior descending artery; LCX Left circumflex artery; RCA Right coronary artery; DES Drug-eluting stent; BRS Bioresorbable scaffold; DCB Drug-coated balloon